Cost-utility Analysis of Second-generation Direct-acting Antivirals for Hepatitis C

Background: Hepatitis C virus (HCV) can lead to increased mortality, disability, and liver transplantation if left untreated, it is associated with a possible increase in disease burden the future, all of which would surely have significant impact on health system. New antiviral regimens are effective treatment yet expensive. Objectives: The purpose present study was assess cost-effectiveness three medication regimens, namely, ledipasvir/sofosbuvir (LDV/SOF), velpatasvir/sofosbuvir, daclatasvir/sofosbuvir (DCV/SOF) for HCV patients genotype 1 Iran. Methods: A Markov model lifetime horizon developed predict costs outcomes mentioned therapy strategies. final outcome quality-adjusted life-years (QALYs), obtained using previously published studies. conducted from perspective Health Ministry; therefore, only direct medical were estimated. results provided as incremental ratio (ICER) per QALY. Ultimately, one-way probabilistic sensitivity analyses used measure strength results. Results: showed that QALYs LDV/SOF, DCV/SOF, VEL/SOF 13.25, 13.94, 14.61, 4,807, 7,716, 4,546$, respectively. regimen had lower higher effectiveness than LDV/SOF DCV/SOF making dominant strategy. tornado diagram highest chronic hepatitis (CHC) compensated cirrhosis (CC) state costs. Moreover, scatter plots therapeutic strategy 73% simulations compared 66% DCV/SOF; moreover, acceptable region 92% below threshold. Therefore, considered most cost-effective threshold 69% LDV/SOF. more Conclusions: According results, suggested be first line 1. second-line regimen.